Coherus Oncology shares fall on $50.1M dilutive stock offering
28.6 million share pricing at 13% discount raises funds for LOQTORZI commercialization as oncology company builds market presence
Coherus Oncology shares declined in Thursday trading after the biopharmaceutical company announced the pricing of a $50.1 million public offering that will dilute existing shareholders by nearly 24%. The offering prices 28.6 million shares at $1.75 each, representing a 12.9% discount to the stock's recent trading price around $2.01.
The Redwood City, California-based company intends to use the net proceeds to support the ongoing commercialization of LOQTORZI (toripalimab-tpzi), advance clinical development of its product pipeline, and fund general working capital. The offering is expected to close around February 17, 2026, subject to customary closing conditions.
Underwriters TD Cowen, Guggenheim Securities, and Oppenheimer & Co. have been granted a 30-day option to purchase up to an additional 4.3 million shares, which if exercised would increase total gross proceeds to approximately $57.6 million and further dilute shareholders.
LOQTORZI, a next-generation PD-1 inhibitor, received FDA approval in October 2023 for the treatment of adults with metastatic or recurrent nasopharyngeal carcinoma. The commercial launch in the United States began in January 2024, giving the company roughly two years to establish market presence before this capital raise.
The 23.6% dilution comes at a challenging time for the oncology specialist, which has a market capitalization of approximately $247 million and was trading near its 52-week high of $2.62 before the announcement. Despite the near-term pressure on existing shareholders, analysts maintain an optimistic long-term outlook.
Oppenheimer initiated coverage in January 2026 with an "Outperform" rating and a $10 target price, suggesting potential upside of more than 400% from current levels. The average analyst price target ranges from $5.51 to $6.75, with several analysts maintaining "Buy" or "Strong Buy" ratings even after accounting for the dilutive offering.
One analyst acknowledged the equity raise and potential dilution but suggested a "neutral" net impact when considering strong early uptake of LOQTORZI and the company's solid cash runway. The company also updated its at-the-market equity offering program in January, allowing it to sell up to $64.9 million in common stock for additional capital-raising flexibility.
Coherus's pipeline includes other oncology candidates such as tagmokitug and casdozokitug, which the company is developing both independently and through potential partnerships. The strategy focuses on expanding LOQTORZI's label to additional indications while building a broader immuno-oncology platform.
Financial metrics present a mixed picture. While the company reported a net margin of 55.8%, it maintains negative EBITDA of approximately $79.8 million and an Altman Z-Score indicating potential financial distress. Technical indicators show neutral sentiment, with the stock's relative strength index at 54.52, though the price recently crossed above its 200-day moving average on February 10—a short-term bullish signal that preceded the offering announcement.
Institutional investors hold approximately 43.5% of outstanding shares, while insiders control 18.6%, providing some stability despite the significant dilution. The company's ability to demonstrate progress in LOQTORZI commercialization and pipeline development will be critical for maintaining investor confidence as it absorbs the new share issuance.